Evidence map›Paper›PMID 40600471›Full record

ArticleJournal of the International AIDS Society2025

Feasibility and acceptability of persons on long-acting cabotegravir for HIV prevention in the SEARCH Dynamic Choice HIV Prevention trial extension in rural Kenya and Uganda: a longitudinal cohort study.

Elijah R Kakande, Laura B Balzer, Jane Kabami, James Ayieko, Gabriel Chamie, Nicole Sutter, Helen Sunday, Marilyn Nyabuti, Janice Litunya, Carol Camlin and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the International AIDS Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Elijah R KakandeInfectious Diseases Research Collaboration, Kampala, Uganda.
Laura B BalzerDivision of Biostatistics, University of California Berkeley, Berkeley, California, USA.
Jane KabamiInfectious Diseases Research Collaboration, Kampala, Uganda.
James AyiekoKenya Medical Research Institute, Nairobi, Kenya.ORCID https://orcid.org/0000-0002-0324-4006
Gabriel ChamieDivision of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-5860-8081
Nicole SutterDivision of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Helen SundayInfectious Diseases Research Collaboration, Kampala, Uganda.
Marilyn NyabutiKenya Medical Research Institute, Nairobi, Kenya.
Janice LitunyaKenya Medical Research Institute, Nairobi, Kenya.
Carol CamlinDivision of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-5615-1164
Jason Johnson-PeretzDivision of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Jenny TempleDivision of Biostatistics, University of California Berkeley, Berkeley, California, USA.
Geoff LavoyInfectious Diseases Research Collaboration, Kampala, Uganda.
Catherine KossDivision of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Maggie CzarnogorskiDepartment of Digital Innovation and Implementation Science, ViiV Healthcare, Durham, North Carolina, USA.
Maya L PetersenDivision of Biostatistics, University of California Berkeley, Berkeley, California, USA.
Moses R KamyaInfectious Diseases Research Collaboration, Kampala, Uganda.
Diane V HavlirDivision of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-0761-3136

Funding

A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East AfricaU01AI150510 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V, KAMYA, MOSES ROBERT · 2020 to 2025
$23.4M
NHLBI NIH HHSNIAID NIH HHS U01 AI150510NIMH NIH HHS 1U01AI150510U.S. National Institute of Allergy and Infectious Diseases (NIAID)
6 · The paper itself

Abstract

introductionInjectable cabotegravir (CAB-LA) is highly effective for HIV prevention, but real-world implementation studies in Africa are ongoing. We assessed feasibility and acceptability among participants who used CAB-LA in the SEARCH Dynamic Choice HIV Prevention extension study in rural Uganda and Kenya.

methodsFrom January 2023 to December 2024, we followed females and males who were aged ≥ 15 years, with self-assessed risk for HIV acquisition, in the intervention arm of the SEARCH Dynamic Choice HIV Prevention extension study, and received at least one CAB-LA injection during the first 48 weeks. To assess the feasibility and acceptability of CAB-LA, we designed quantitative surveys based on the Theoretical Framework for Acceptability. Surveys were administered at CAB-LA initiation, after 24 and 48 weeks of use, and discontinuation of CAB-LA.

resultsOf 487 intervention arm participants, 274 (56%) started CAB-LA (183 females; 91 males; 79 youth aged 15-24 years). Of whom, 264 completed the survey at initiation, 206 after 24 weeks on CAB-LA, 201 after 48 weeks on CAB-LA and 69 at discontinuation of CAB-LA. Most participants (65%; 171/264) reported choosing CAB-LA because it was easier to take than pills, and nearly all (99%; 261/264) had limited knowledge of CAB-LA prior to the study. Concerns for side effects were the largest anticipated and experienced barrier to CAB-LA. Overall and with subgroups, satisfaction with CAB-LA was high at 24 weeks (97%; 200/206) and 48 weeks (96%; 193/201). Nearly all participants reported that taking CAB-LA was easy at 24 weeks (95%; 195/206) and 48 weeks (99%; 198/201). At CAB-LA discontinuation, 83% (57/69) were likely to extremely likely to recommend CAB-LA to a friend: 80% (20/25) of males, 84% (37/44) of females, 100% (19/19) of youth and 76% (38/50) of older adults.

conclusionsIn rural Uganda and Kenya, over half of participants in the SEARCH trial who were offered choice of oral PrEP/PEP or CAB-LA chose and started CAB-LA during the first 48 weeks. For both males and females and younger and older adults, CAB-LA was both feasible and acceptable to deliver with satisfaction remaining high throughout the study, and nearly all reporting ease of use. CLINICAL TRIAL NUMBER: 05549726.

Indexed as

Anti-HIV AgentsHIV InfectionsPatient Acceptance of Health CarePyridonesAdolescentAdultDiketopiperazinesFeasibility StudiesFemaleHumansKenyaLongitudinal StudiesMaleMiddle AgedRural PopulationUgandaAnti-HIV AgentscabotegravirDiketopiperazinesPyridonesacceptabilitydynamic choicefeasibilityHIV preventionimplementationlong‐acting injectable cabotegravir

Identifiers

PMID40600471
PMCPMC12215826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.